Shots:

• The multiple expansion cohort will assess the safety- tolerability- drug levels- molecular effects- and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation
• Strata Oncology will identify patients to be considered for enrollment into Mirati's P-I/II study. The Strata Trial provides tumor molecular profiling for patients with advanced cancer paired with a portfolio of biomarker-guided clinical trials
• Strata Oncology utilizes StrataNGS which is a molecular profiling test optimized for performance on tumor tissue samples as small as 0.5mm² surface area. MRTX849 is a novel KRAS G12C selective inhibitor

­ Ref: PRNewswire | Image: Strata Oncology